The study, led by Andrew McGarry of Clintrex Research Corporation and Cooper Medical School at Rowan University, together with colleagues at ABLi Therapeutics and the University of Rochester School of Medicine, applied time-to-event methodology, a statistical framework borrowed from fields such as oncology and cardiology, to data from four early interventional studies and one observational cohort in early, untreated Parkinson’s disease. Rather than comparing average score changes between groups, time-to-event analysis asks a simpler and arguably more clinically resonant question: how long does it take before a patient experiences a defined amount of worsening, and what proportion of patients reach that threshold within a given period?

The technical appeal of this approach is substantial. Traditional endpoints in Parkinson’s trials typically rely on mean changes in scores on the Unified Parkinson’s Disease Rating Scale, or its modern revision, the Movement Disorders Society version known as the MDS-UPDRS. Mean-change endpoints can be diluted by patients who improve slightly, stay stable, or fluctuate for reasons unrelated to the disease process, and they are vulnerable to confounding the moment a participant begins dopaminergic treatment, which can mask underlying progression. A time-to-event endpoint, by contrast, focuses on the first time a participant crosses a pre-specified worsening threshold, an event that is binary, interpretable, and directly tied to something a clinician and patient can recognize as real deterioration.

In this analysis, the researchers examined two complementary dimensions of the disease. Part 3 of the MDS-UPDRS captures the motor examination, the tremor, rigidity, slowness, and gait changes that a clinician observes during a structured assessment. Part 2 captures the patient’s own report of functional experiences in daily life, such as difficulty with dressing, eating, handwriting, and walking. The team asked how many participants, while remaining untreated over a 12-month period, crossed worsening thresholds of varying magnitudes on each of these scales, and whether crossing a motor examination threshold was accompanied by concurrent functional decline.

The headline finding concerns the feasibility of demanding large, clinically meaningful changes. At the most stringent thresholds examined, between 32 and 42 percent of participants across the cohorts reached a worsening of at least 4 points on Part 2 within 12 months, while between 27 and 34 percent reached a worsening of at least 7 points on Part 3. Those proportions may sound modest, but in trial-design terms they are consequential. A trial powered on an event rate of roughly one in three participants over a year is a very different, and far more achievable, proposition than one requiring the majority of participants to deteriorate substantially before any signal can emerge.

As the thresholds were relaxed, the picture changed predictably. Lowering the bar for what counts as worsening increased the proportion of participants achieving it in every cohort analyzed, a consistent dose-response-like relationship between threshold stringency and event frequency. This gradient gives trial designers a tunable dial: a sponsor can choose a threshold that is clinically defensible and simultaneously yields enough events within the planned follow-up to give the study adequate statistical power. The analysis suggests that 12-month studies powered for large worsening thresholds in motor examination scores are genuinely feasible in early Parkinson’s disease, a conclusion that could influence how the next generation of disease-modification trials is designed.

Perhaps the most clinically important finding is the coupling between the motor examination and daily function. Many participants who crossed each Part 3 threshold experienced simultaneous worsening on Part 2, and higher motor examination thresholds were generally associated with greater functional worsening. In plain terms, when the examiner’s findings deteriorated by a meaningful amount, the patient’s lived experience deteriorated too. This linkage matters because it addresses a persistent criticism of rating-scale endpoints: that a few points on a clinician’s checklist might not translate into anything a patient actually feels. Here, the motor examination thresholds were anchored to concurrent functional decline, strengthening the argument that these are not arbitrary statistical constructs but markers of genuine clinical change.

The confounding problem that motivated the work deserves emphasis. In early Parkinson’s disease, the standard of care is to begin symptomatic treatment, typically levodopa or a dopamine agonist, when symptoms begin to interfere with daily life. Once treatment starts, the underlying disease trajectory becomes obscured, because dopaminergic medication improves motor scores regardless of whether the disease itself has slowed. A trial that allows treatment initiation partway through risks comparing groups in which different proportions of participants have started medication, contaminating the endpoint. Time-to-event analyses that focus on the untreated period, as this study does, sidestep much of that contamination by capturing progression before the therapeutic veil descends, and by treating treatment initiation itself as a censoring event or a competing consideration in the analysis.

The study drew on data from both interventional trials and the Parkinson’s Progression Markers Initiative, the large observational study funded by the Michael J. Fox Foundation for Parkinson’s Research and its partners. Combining randomized trial cohorts with a naturalistic observational cohort is a strength, because it tests whether the event rates are reproducible across different settings, populations, and assessment practices. The consistency of the pattern, with proportions of untreated worsening rising as thresholds relaxed in all cohorts, suggests that the findings are not an artifact of any single study’s design or population. The work was funded by ABLi Therapeutics, and the authors declared no competing interests in the published report.

For the field, the implications point toward a practical redesign of early-phase disease-modification trials. Sponsors evaluating candidate therapies in newly diagnosed, untreated patients can now consider endpoints built on time to a large, clinically anchored worsening event, with realistic expectations about event rates over 12 months and a defensible link between the motor examination and patients’ daily functioning. That could mean smaller trials, shorter trials, or trials with a clearer path to demonstrating benefit that regulators, clinicians, and patients can all interpret in the same way. It is a reminder that sometimes the most powerful question in medicine is not how much a patient changed, but how long it took for the change to become undeniable.

Subject of Research: Time-to-event analysis of motor and functional outcomes in early untreated Parkinson's disease clinical trials

Article Title: Time-to-event analyses of motor examination and functional outcomes in early Parkinson’s disease clinical trials

Article References: McGarry, A., Meyer, C. R., Kieburtz, K., Dubow, J., Werner, M. H., & Venuto, C. (2026). Time-to-event analyses of motor examination and functional outcomes in early Parkinson’s disease clinical trials. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01578-3

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01578-3

Keywords: Parkinson's disease, time-to-event analysis, clinical trials, MDS-UPDRS, motor progression, disease-modifying therapy, clinical endpoints, neurology, observational study, PPMI, untreated patients, functional outcomes

The study, led by Shayan Zadegan and colleagues, focused on three biomarkers that each capture a different facet of the disease’s underlying biology. The first is the alpha-synuclein seed amplification assay (alphaSyn-SAA), a technique that detects the misfolded alpha-synuclein protein aggregates considered central to Parkinson’s pathology. The second is alpha-synuclein carried inside neuron-derived extracellular vesicles (NDEVs), microscopic membrane bubbles released by brain cells that can be fished out of a blood sample using an antibody against the L1CAM surface marker. The third is microRNA-7-5p (miR-7-5p), a small non-coding RNA that acts as a molecular brake on alpha-synuclein production and aggregation, and which also suppresses the NLRP3 inflammasome, a key driver of neuroinflammation. Together, these markers trace the intertwined axis of protein misfolding and inflammatory dysregulation that defines the disease.

The rationale for looking at miR-7-5p in blood is particularly intriguing. In the brains of people with established Parkinson’s disease, miR-7-5p is downregulated in the substantia nigra, consistent with its role as a protective regulator that normally restrains alpha-synuclein. Yet the new analysis, corroborating earlier work, found the opposite pattern in the blood of prodromal patients: those who went on to phenoconvert to Parkinson’s more rapidly had higher baseline levels of the microRNA. The authors interpret this as a compensatory response, with the body ramping up production of this protective molecule as the disease begins its assault. If that interpretation holds, elevated blood miR-7-5p would function less like a smoking gun and more like an alarm bell, signaling that the brain’s defenses are actively engaged against an unfolding pathology.

The data came from the PPMI, a large longitudinal biobank spanning North America and Europe that enrolls people over 60 who carry specific prodromal risk factors: REM sleep behavior disorder, hyposmia paired with a dopamine transporter imaging deficit, or genetic risk variants in the SNCA, LRRK2, or GBA genes. Among 313 prodromal participants with miR-7-5p or NDEV alpha-synuclein measurements, 79, or 25.2 percent, developed clinical Parkinson’s disease during follow-up. The cohort was genetically diverse, with nearly half carrying LRRK2 mutations and more than a quarter carrying GBA mutations, a composition that matters because the alphaSyn-SAA performs unevenly across these groups.

Using Cox proportional hazards regression, the researchers found that each unit increase in baseline log miR-7-5p was associated with a 1.60-fold increase in the hazard of phenoconversion, an association that remained robust after adjusting for age and sex. When participants were dichotomized using a data-derived cutoff, those above the threshold faced 2.19 times the risk of conversion compared with those below it. The NDEV alpha-synuclein results followed a strikingly different statistical pattern: as a continuous variable, the marker showed no significant association with conversion, but once participants were split at a derived cutoff, elevated levels conferred a 4.46-fold increased hazard in adjusted models. The authors suggest this divergence may reflect a biological tipping point, a threshold of pathological protein burden beyond which motor decline becomes imminent, though they caution that unstable threshold selection and overfitting in the modest sample could also explain the discrepancy.

The alphaSyn-SAA itself performed as expected. Participants with a positive assay at baseline had 3.62 times the risk of phenoconversion in adjusted models, confirming its status as one of the strongest single predictors available. But the most compelling result emerged when the spinal fluid assay and the blood microRNA measurement were combined. Individuals who were both alphaSyn-SAA positive and above the miR-7-5p threshold had 4.31 times the risk of conversion in adjusted models, a hazard ratio exceeding that of either marker alone. This synergy is especially valuable for the genetically at-risk populations that dominate the prodromal cohort. Previous work has shown that while 86 percent of sporadic prodromal patients test positive on the alphaSyn-SAA, only 28 percent of GBA carriers, 20 percent of LRRK2 carriers, and none of the SNCA carriers do, leaving a dangerous blind spot that a blood-based microRNA measurement appears well positioned to fill.

The methodological machinery behind these measurements is worth appreciating. Neuron-derived extracellular vesicles were captured from just 250 microliters of serum using immunocapture against L1CAM, a transmembrane protein that serves as a fingerprint of neuronal origin. Because the vesicles’ lipid bilayer shields their cargo from the RNases and proteases that circulate in blood, they offer a protected, non-invasive window into brain biochemistry. Validation studies using nanoparticle analysis, western blotting, confocal microscopy, and nanoscale flow cytometry have confirmed that the captured particles carry neuronal markers such as beta-tubulin alongside canonical vesicle markers like Alix and CD81, and fall in the expected 100 to 200 nanometer size range. The detection antibody, MJFR1, binds both monomeric and aggregated forms of alpha-synuclein, providing a comprehensive readout of the total pathological protein load. Meanwhile, whole blood miRNA sequencing on an Illumina NovaSeq6000 platform captured the systemic transcriptomic picture, reflecting both intracellular and extracellular microRNA pools.

The strategic payoff of this work lies in clinical trial design. Disease-modifying therapies for Parkinson’s have repeatedly failed, and one likely culprit is the inclusion of prodromal participants who carry a low immediate risk of conversion. These slow progressors inject statistical noise into longitudinal datasets, masking genuine therapeutic effects and forcing trials to balloon in size and cost. By enriching trials with participants selected through the combined biomarker model, researchers could filter out slow converters and concentrate statistical power on the most aggressive forms of the disease, dramatically improving the odds of detecting a neuroprotective signal in Phase II and III studies. The blood-based approach also removes the procedural burden of serial lumbar punctures, lowering barriers to participation and enabling the high-frequency longitudinal screening that modern prevention trials demand.

Important caveats remain. The NDEV alpha-synuclein analysis rested on only 101 participants, of whom just 18 converted, and the authors explicitly label those findings exploratory and hypothesis-generating. The derived cutoffs for both blood markers showed substantial variability under bootstrap resampling, and the authors stress that they require validation in independent cohorts before any clinical use. Sample sizes were too restrictive for subgroup analyses by genetic status, leaving open the question of whether miR-7-5p dynamics differ between LRRK2 carriers, whose mutations heighten microglial inflammatory responses, and people with idiopathic disease. Still, with Parkinson’s prevalence projected to surge 76 percent by 2050 to roughly 267 cases per 100,000 people worldwide, the stakes could hardly be higher. If larger studies confirm these findings, a routine blood draw paired with an existing spinal fluid assay could shift neurology from reactive symptom management toward proactive, biologically targeted intervention, catching the disease while there are still neurons left to save.

Subject of Research: Blood and cerebrospinal fluid biomarkers for predicting phenoconversion to Parkinson's disease in prodromal patients

Article Title: microRNA‐7‐5p and α‐Synuclein SAA Predict Parkinson's Disease Phenoconversion

Article References: Zadegan, S., Velammal, P., Muthiah, K., Jatty, M., & Adams, C. (2026). microRNA ‐7‐5p and α‐Synuclein SAA Predict Parkinson's Disease Phenoconversion. Annals of Clinical and Translational Neurology, Article acn3.70539. https://doi.org/10.1002/acn3.70539

Image Credits: AI Generated

DOI: 10.1002/acn3.70539

Keywords: Parkinson's disease, microRNA-7-5p, alpha-synuclein, seed amplification assay, extracellular vesicles, biomarkers, phenoconversion, prodromal, PPMI, liquid biopsy, neurodegeneration, clinical trials